Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CDA | P32320 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9202125 | 0.95 | KDM4E (0.39) | KDM4EALDH1A1OPRM1PDE7ATGM2 | |
| SCHEMBL3093245 | 0.93 | PDE7A (0.41) | KDM4EALDH1A1OPRM1PDE7AHSD11B1 | |
| SCHEMBL14244119 | 0.91 | — | — | |
| SCHEMBL17138754 | 0.89 | CDA (0.42) | KDM4EALDH1A1NPY5RMAPK1NOS3 | |
| SCHEMBL19271812 | 0.84 | CDA (0.42) | KDM4EALDH1A1OPRM1NPY5RNOS3 | |
| SCHEMBL6531351 | 0.84 | NOS1 (0.42) | KDM4EALDH1A1OPRM1NPY5RNOS3 | |
| SCHEMBL726957 | 0.84 | HTR2C (0.40) | KDM4EALDH1A1TGM2NPY5RHSD11B1 | |
| SCHEMBL10807373 | 0.83 | TGM2 (0.34) | KDM4EALDH1A1OPRM1PDE7ATGM2 | |
| SCHEMBL5951577 | 0.83 | CDA (0.38) | ALDH1A1OPRM1NOS3NOS1KMT2A | |
| SCHEMBL11215508 | 0.83 | CDA (0.44) | KDM4EALDH1A1OPRM1NPY5RHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4461734-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4480953-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12351572-B2 | Substituted 1,2,4-triazoles as TYK2 inhibitors | ALUMIS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-113490664-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4480953-A2 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4461734-A2 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-3870579-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12060343-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2019047686-A1 | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190071413-A1 | Cyclobutyl-Imidazolidinone Compounds | ELI LILLY AND COMPANY | 2019-03-07 | — | — | US | disclosed |
| US-20190071413-A1 | Cyclobutyl-Imidazolidinone Compounds | ELI LILLY AND COMPANY | 2019-03-07 | — | — | US | disclosed |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071413-A1 | Cyclobutyl-Imidazolidinone Compounds | SLC10A1, CPT1A, SLC10A2 | KDM4E 863/4885ALDH1A1 1323/4885OPRM1 4318/4885 |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | KDM4E 1254/4885ALDH1A1 2882/4885OPRM1 3252/4885 |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | KDM4E 1254/4885ALDH1A1 2882/4885OPRM1 3252/4885 |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | KDM4E 92/4885ALDH1A1 539/4885OPRM1 2529/4885 |
| US-12351572-B2 | Substituted 1,2,4-triazoles as TYK2 inhibitors | TYK2, JAK1, JAK3 | KDM4E 393/4885ALDH1A1 3054/4885OPRM1 4153/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | KDM4E 1254/4885ALDH1A1 2882/4885OPRM1 3252/4885 |
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK3 | KDM4E 444/4885ALDH1A1 4455/4885OPRM1 4032/4885 |
| US-12060343-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | KDM4E 577/4885ALDH1A1 3344/4885OPRM1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.